Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Tolerability of GS-2426 in Participants With Advanced MTAP-Deleted Solid Tumors

NCT07601243 is registered in ClinicalTrials.gov with Gilead Sciences as lead sponsor.

NCT NCT07601243
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07601243 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multicenter, Open-Label Clinical Study to Evaluate the Safety and Tolerability of GS-2426 in Participants With Advanced MTAP-Deleted Solid Tumors
Lead sponsor
Gilead Sciences
Phase
Phase 1
Overall status
Recruiting
Start date
June 2, 2026
Completion date
January 31, 2029
Enrollment
174 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

advanced solid tumors